Vertical

Before COVID-19, we all recognized that a global shift towards remote work had become a trend. However, the response to the COVID-19 pandemic greatly accelerated this movement, almost doubling the number of remote workers. 

We are extremely focused on accelerating our growth of pet owner acquisition in Malaysia and constantly experimenting with new growth channels to scale our business. Within the coming months, we hope to also further develop our proprietary technology which will allow us to distribute our product and manage our claims services smartly and at scale. To…

Besides Taiwan, 3 SQUARE is looking to expand into Hong Kong, Singapore, Malaysia, Thailand, Indonesia, The Philippines and Japan.

The startup seeks to tap into a growing opportunity in the retail investing space in Vietnam. The country of 97 million population has more than 75 percent internet users transacting money digitally, but only roughly 3.14 million--or 3.2 percent of the population-- investing in securities.

The present pandemic and the need for physical distancing caught the imagination of brands to develop a hybrid platform. As a result, the customers experience physical and digital shopping benefits and transform their buying experience to the next level. It is where "phygital" services came about. 

KLAR plans to use the funding for four business goals including R&D development to achieve economies of scale and treatment optimization, expand the company's talent base, enhance branding, and venture into complementary product offerings

If the pandemic has taught businesses one thing, it’s that keeping your workforce organized and motivated, especially when working in remote teams, is crucial. Consider investing in these HR technology tools and initiatives.

Fairbanc's proprietary data science and machine learning platform leverages supply-chain data of FMCG distributor partners which allows financial institutions to assess credit risk and extend working capital to MSMEs with limited credit history and collaterals, according to the disclosure.

Proceeds from the funding will be used to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities, the company added.